Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
A new myeloid cell engager enters the clinic
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
